Patient-Centric Mission.
Asset-Centric Approach.
We’re pursuing our Orexin Receptor 2 Agonist Program to bring potentially transformative treatment options to patients with sleep-wake, neurological, neurodegenerative and neuropsychiatric disorders.
We are leaders, innovators, and scientists aiming to pursue medicines that are transformational for patients.
Latest News
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares